NHF’s QMS is ISO 9001:2015 Certified

Government of Jamaica

FIVE NEW ACTIVE INGREDIENTS ADDED TO NHF DRUG LIST Subsidies For Insulin Analogues Increased By 300%

FIVE NEW ACTIVE INGREDIENTS ADDED TO NHF DRUG LIST Subsidies For Insulin Analogues Increased By 300%

Patients enrolled with the National Health Fund (NHF) will now be able to obtain benefits for five new Active Pharmaceutical Ingredients that treat eight of the fifteen chronic illnesses on the Individual Benefits Programme . The new additions are Deflazacort, Lamotrigine, Tramadol, Zinc Hyaluronate and Diosmin.

Deflazacort, is used for the treatment of Asthma and Arthritis and enjoys a NHF subsidy of $60.38 for each 6 milligram tablets on the Calcort label.

Lamotrigine, is used for the treatment of Epilepsy and Major Depression and tablets are available in strengths of 25 Milligrams, 50 Milligrams and 100 Milligrams. The NHF Subsidy for these tablets on the Lamictal and Lamotrigine-PMS labels, is $10.66 for each 25 Milligram. The chewable tablets on the Lamictal label should be great news for treating the children enrolled for epilepsy with the NHF.

Tramadol, which is now listed under Arthritis and is an adjunct for Breast and Prostate Cancer, is available as drops, long acting tablets and capsules. The NHF subsidy is $36.40 for each 50 Milligram capsule or tablet on the Adamon and Tramal labels. $650 is the subsidy for each 10 Millilitre bottle of liquid also on the Adamon and Tramal labels.

Zinc Hyaluronate is used for the treatment of Vascular Disease and is an adjunct for Diabetes. It is available in the form of a gel with a NHF subsidy of $847.60 for each 15 Gram tube on the Curiosin label.

Diosmin is now listed under Vascular Disease and has a NHF subsidy of $18.93 for each 300 Milligram tablet on the Venex label.

Three new generic labels have also been added to the NHF Individual Benefits Programme:
Flunil (Fluoxetine) capsules which is used for treating Major Depression with a subsidy of $18.78 for each 20 Milligram capsule; Risperidone-PMS (Risperidone) also for the treatment of Major Depression and Psychosis with a subsidy of $66.26 for each 2 Milligram tablet; The third new label is Bical (Bicalutamide) tablet used for the treatment of Prostate Cancer and enjoys a subsidy of $568.03 for each 50 Milligram tablet.

NHF has also increased the subsidies for insulin analogues by three hundred percent (300%).

An insulin analogue is an altered form of insulin which is manufactures using DNA technology to produce a pharmaceutical preparation that although different from conventional insulin is better able to control glycemic levels with a lower risk of hypoglycemia, in the diabetic.

The Active Pharmaceutical Ingredients benefiting from this increase are Insulin Glargine, Insulin Glulisine; Insulin Lispr; Insulin Lispro and Lispro Protamine; Insulin Aspart; Insulin Aspart and Aspart Protamine.

For further information please visit NHF Website or call 1-888- NHF-CARE

For further information contact:
Rosemarie Lee, Tel. 906-1106 or 535-0909
Shermaine Robotham, Tel. 322- 0809

National Health Fund © 2024. All Rights Reserved.